Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 37 - Drugs for immunological or allergic disorders
Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
09/2000
09/28/2000WO2000056704A1 Hydroxamic and carboxylic acid derivatives
09/28/2000WO2000056405A2 Human tumor necrosis factor receptor-like 2
09/28/2000WO2000056403A1 UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY HMG-CoA REDUCTASE INHIBITORS
09/28/2000WO2000056365A1 Use of trehalose for stabilising a liquid vaccine
09/28/2000WO2000056363A1 Treatment of lfa-1 associated disorders with increasing doses of lfa-1 antagonist
09/28/2000WO2000056362A2 Polycationic carbohydrates as immunostimulants in vaccines
09/28/2000WO2000056361A2 Vaccine composition
09/28/2000WO2000056360A2 Vaccine against antigens from bacteriae
09/28/2000WO2000056359A2 Vaccine against streptococcus pneumoniae
09/28/2000WO2000056358A2 Vaccine against streptococcus pneumoniae capsular polysaccharides
09/28/2000WO2000056356A2 Induction of antigen-specific unresponsiveness by glioblastoma culture supernatants (gcs)
09/28/2000WO2000056346A1 Stable oil-in-glycerin emulsion
09/28/2000WO2000056341A1 Chemical compounds and their uses
09/28/2000WO2000056338A1 Quinazoline formulations and therapeutic use thereof
09/28/2000WO2000056331A1 Inhibitors of impdh enzyme
09/28/2000WO2000056304A2 Anti-inflammatory uses of manzamines
09/28/2000WO2000056303A2 Treatment of immune diseases
09/28/2000WO2000056282A1 Particle based vaccine composition
09/28/2000WO2000056166A1 Animal plasma supplement for aquaculture
09/28/2000WO2000041497A3 Use of apoptosis inducing agents in the treatment of (auto)immune diseases
09/28/2000WO2000040693A3 Expression of secreted human alpha-fetoprotein in transgenic animals
09/28/2000WO2000035428A3 Tricyclic nitrogen heterocycles as pde iv inhibitors
09/28/2000WO2000023592A9 Minimal promoters and uses thereof
09/28/2000WO2000023114A3 Polymer conjugates of interferon beta- 1a and their uses
09/28/2000WO2000022143A3 Protein kinase homologs
09/28/2000WO2000022142A3 Cell signaling polypeptides and nucleic acids
09/28/2000WO2000021559A3 Blocking factor b to treat complement-mediated immune disease
09/28/2000WO2000020447A3 Polynucleotides coding for secreted polypeptides, some having similarity to syncollin or claudin or cytokine, their therapeutic uses
09/28/2000WO2000018796A3 Secretory protein- zsig48
09/28/2000WO2000015793A3 Human gpcr proteins
09/28/2000WO1999067417A3 Fitness assay and associated methods
09/28/2000DE19913692A1 Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen Mechanically stable pharmaceutical dosage forms containing liquid or semisolid surface-active substances
09/28/2000CA2855415A1 Phenylalanine derivatives
09/28/2000CA2669512A1 Human antibodies that bind human il-12 and methods for producing
09/28/2000CA2377383A1 Apoptosis related genes
09/28/2000CA2368733A1 Phenylalanine derivatives
09/28/2000CA2368229A1 50 human secreted proteins
09/28/2000CA2368223A1 48 human secreted proteins
09/28/2000CA2368210A1 50 human secreted proteins
09/28/2000CA2368187A1 Upregulation of type iii endothelial cell nitric oxide synthase by hmg-coa reductase inhibitors
09/28/2000CA2368047A1 Chemokine receptor binding heterocyclic compounds
09/28/2000CA2368041A1 Indolinone compounds as kinase inhibitors
09/28/2000CA2367963A1 Hydroxamic and carboxylic acid derivatives
09/28/2000CA2367866A1 Pyridine and pyrimidine derivatives and their use as inhibitors of cytokine mediated disease
09/28/2000CA2367861A1 Quinazolines and therapeutic use thereof
09/28/2000CA2367620A1 47 human secreted proteins
09/28/2000CA2367488A1 Retroviral vectors comprising functional and non-functional splice donor and splice acceptor sites
09/28/2000CA2367262A1 Treatment of immune diseases
09/28/2000CA2367132A1 Induction of antigen-specific unresponsiveness by glioblastoma culture supernatants (gcs)
09/28/2000CA2367025A1 Treatment of lfa-1 associated disorders with increasing doses of lfa-1 antagonist
09/28/2000CA2366998A1 Quinazoline formulations and therapeutic use thereof
09/28/2000CA2366908A1 Vaccine composition
09/28/2000CA2366877A1 Chemical compounds and their uses
09/28/2000CA2366869A1 Use of trehalose for stabilising a liquid vaccine
09/28/2000CA2366691A1 48 human secreted proteins
09/28/2000CA2366613A1 Particle based vaccine composition
09/28/2000CA2366267A1 49 human secreted proteins
09/28/2000CA2366214A1 Dsp-2 dual-specificity map kinase phosphatase
09/28/2000CA2366152A1 Streptococcus pneumoniae vaccine
09/28/2000CA2366132A1 48 human secreted proteins
09/28/2000CA2365405A1 Human tumor necrosis factor receptor-like 2
09/28/2000CA2365296A1 Vaccine
09/28/2000CA2365255A1 Human tumor necrosis factor receptor tr9
09/28/2000CA2365247A1 49 human secreted proteins
09/28/2000CA2365244A1 Calanolides for inhibiting btk
09/28/2000CA2365243A1 Human transmembrane proteins
09/28/2000CA2365238A1 48 human secreted proteins
09/28/2000CA2365223A1 46 human secreted proteins
09/28/2000CA2365104A1 Anti-p53 antibodies
09/28/2000CA2365081A1 Immunomodulatory steroids, in particular the hemihydrate of 16.alpha.-bromoepiandrosterone
09/28/2000CA2361221A1 Novel protein which induces chondrocyte differentiation
09/27/2000EP1038872A1 4-Phenyl-4-heteroarylpiperdine derivatives as opioid receptor ligands
09/27/2000EP1038864A1 Novel metalloproteinase inhibitors
09/27/2000EP1038863A2 Substituted dimeric compounds, process for their preparation and pharmaceutical compositions thereof
09/27/2000EP1038530A2 Immunomodulator comprising DNA
09/27/2000EP1038019A1 NOVEL ribB
09/27/2000EP1038003A1 Cyclic gmp phosphodiesterase
09/27/2000EP1038002A1 Ubiquitin-like conjugating protein
09/27/2000EP1037998A1 guaA POLYPEPTIDES
09/27/2000EP1037995A1 Human interferon-epsilon: a type 1 interferon
09/27/2000EP1037980A1 G-protein coupled receptors associated with immune response
09/27/2000EP1037967A2 Human phosphatases
09/27/2000EP1037927A2 Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
09/27/2000EP1037917A1 Recombinant nodavirus compositions and methods
09/27/2000EP1037908A2 Human tumor necrosis factor-r2-like proteins
09/27/2000EP1037906A1 Cyclopeptide derivatives with integrin inhibitor properties
09/27/2000EP1037898A1 Secreted proteins
09/27/2000EP1037889A1 Novel compounds
09/27/2000EP1037887A1 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability
09/27/2000EP1037670A2 Agent for gene therapy of tumor, neurodegenerative, cardiovascular and autoimmune diseases
09/27/2000EP1037665A1 Methods and compositions for inhibiting tumor cell growth
09/27/2000EP1037663A2 Methods to treat undesirable immune responses
09/27/2000EP1037662A1 Method to enhance an immune response of nucleic acid vaccination
09/27/2000EP1037660A1 ribB
09/27/2000EP1037658A1 Ifnar2/ifn complex
09/27/2000EP1037653A1 Compositions and methods for regulating phagocytosis and icam-1 expression
09/27/2000EP1037651A1 Small peptides and methods for treatment of asthma and inflammation
09/27/2000EP1037645A1 Processes of making north american ginseng fractions, products containing them, and use as immunomodulators
09/27/2000EP1037635A1 Compounds and methods
09/27/2000EP1037620A1 Use of formoterol in medicament for inflammation/allergy in upper airways
1 ... 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 ... 1172